Tavistock revenues jump 14% amid year of acquisitions

Bought LEBC research firm

clock • 1 min read

Revenues at Tavistock’s advisory business surpassed £32m in the year to 31 March 2022, a 14% jump compared to the entire group’s revenues for the year prior, the company said in a trading update.

Tavistock declared an interim dividend of 0.07p per share, 40% higher than the dividend paid to shareholders in October last year. The firm completed the sale of its £1bn investment management business to Titan Wealth last year for a cash consideration of £40m, together with a 10-year earn out period. The year ending 31 March 2022 was the most successful trading year in its history, according to the firm. It also acquired research firm LEBC Hummingbird, from advisor LEBC, for £3m, prior to which it acquired a 21% interest in LEBC. LEBC has an estimated £4.2bn in assets under adv...

To continue reading this article...

Join Professional Adviser for free

  • Unlimited access to real-time news, industry insights and market intelligence
  • Stay ahead of the curve with spotlights on emerging trends and technologies
  • Receive breaking news stories straight to your inbox in the daily newsletters
  • Make smart business decisions with the latest developments in regulation, investing retirement and protection
  • Members-only access to the editor’s weekly Friday commentary
  • Be the first to hear about our events and awards programmes

Join

 

Already a Professional Adviser member?

Login

More on Companies

PFS' Carla Brown: 'We've built a stronger, more constructive relationship with the CII'

PFS' Carla Brown: 'We've built a stronger, more constructive relationship with the CII'

Professional body has ‘come through some challenging years’

Isabel Baxter
clock 13 November 2025 • 2 min read
WH Ireland confirms takeover approach from Team

WH Ireland confirms takeover approach from Team

10 December deadline

Sahar Nazir
clock 13 November 2025 • 1 min read
FNZ raises $650m in funding from institutional shareholders

FNZ raises $650m in funding from institutional shareholders

Aviva, Aberdeen, and Nucleus part of backing

Isabel Baxter
clock 12 November 2025 • 1 min read